Trials / Completed
CompletedNCT00116415
DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
Daily Antiretroviral Therapy (DART 1): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Didanosine Enteric Coated (Ddl-EC) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 65 (planned)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz (EFV), didanosine (ddI)-EC and lamivudine (3TC) leads to improved outcomes, as measured by viral load, CD4 counts, adherence, safety, and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | efavirenz; didanosine EC; lamivudine |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2004-11-01
- Completion
- 2004-11-01
- First posted
- 2005-06-30
- Last updated
- 2011-04-22
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00116415. Inclusion in this directory is not an endorsement.